Recombinant mouse IgG1 isotype control

Recombinant mouse IgG1 isotype control mAb against E. coli β-galactosidase

InvivoGen’s Anti-β-Gal-mIgG1 antibody

InvivoGen provides a recombinant anti-β-Gal-mIgG1 monoclonal antibody (mAb)  that was previously extracted from hybridoma. It is now expressed and produced in chinese hamster ovary (CHO) cells, ensuring reliability and lot-to-lot reproducibility. Thereby, common hybridoma-related drawbacks such as the generation of non-relevant mAbs containing aberrant light chains are avoided. This control antibody targets E. coli's β-galactosidase (β-Gal), an antigen that is not present in mice. In addition, it displays low ADCC (antibody-dependent cell-mediated cytotoxicity) and no CDC (complement-dependent cytotoxicity) effector functions [1].

The sequence of Anti-β-Gal-mIgG1 is 100% murine (constant and variable regions), as the original clone (clone T9C6) was raised in mice using a proprietary method. This feature allows for reduced immunogenicity and risks of fatal hypersensitivity reactions upon repeated mAb injections into mice [2]. 

InvivoGen provides this antibody in two grades:

• In vitro use: Anti-β-Gal-mIgG1
• In vivo use:  Anti-β-Gal-mIgG1 InvivoFit™

All InvivoFit™ products are handled in a clean room, filter-sterilized, and tested for bacterial contaminants. Additionally, this grade guarantees low levels of endotoxins (<1 EU/ml). The buffer formulation is specifically adapted for in vivo studies.

Key features:

• Targets E. coli β-galactosidase antigen 
• Sequence is 100% murine
• Murine IgG1 isotype (constant region)
• Free from non-relevant mAbs found in hybridoma-based productions
• Produced in animal-free facilities and defined media
• Low aggregation < 5%
• InvivoFit™ grade is available

References:

1. Bradbury, A. et al., 2018. When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. mAbs, 10(4), 539–546.
2. Yamazaki T. et al., 2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.

Specifications

Target: E. coli β-galactosidase (β-Gal)

Specificity: no cross-reaction with murine proteins

Clone: T9C6

Source: CHO cells

Isotype: Murine IgG1, kappa

Formulation of Anti-β-Gal-mIgG1: Lyophilized from 0.2 µm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Formulation of Anti-β-Gal-mIgG1 InvivoFit™: Lyophilized from 0.2 µm filtered solution in a sodium phosphate buffer with 5% saccharose

Application: Negative control for murine IgG1 antibodies

Quality control:

• The absence of binding was confirmed by flow cytometry.
• The complete sequence of this antibody has been verified.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.
• The endotoxin level in Anti-β-Gal-mIgG1 InvivoFit™ is <1 EU/mg (determined by a LAL assay).

Contents

Please note: each mAb is sold separately.

Anti-β-Gal-mIgG1

• bgal-mab9-02​: 200 µg, lyophilized

Anti-β-Gal-mIgG1 InvivoFit™

• bgal-mab9-1​: 1 mg, lyophilized
• bgal-mab9-10​: 10 mg, lyophilized

 The product is shipped at room temperature.

 Store lyophilized antibody at -20 °C.

 Lyophilized product is stable for at least 1 year.

 Avoid repeated freeze-thaw cycles.

InvivoFit™

InvivoFit™ is a high-quality standard specifically adapted for in vivo studies. InvivoFit™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and a TLR2 and TLR4 reporter assay.